Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 929 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stereotactic radiotherapy Clear all

Conditions: Prostate Cancer
Interventions: Extended Hypofractionation Radiotherapy, Accelerated Hypofractionation Radiotherapy; Radiation
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 85 Years · Male only
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Anaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid Carcinoma
Interventions: Dabrafenib, Trametinib, Pembrolizumab, Pulsed Stereotactic Ablative Radiotherapy, Ethos; Drug · Biological · Radiation + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Squamous Cell Carcinoma of the Oropharynx
Interventions: Stereotactic Body Radiotherapy; Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: High-Dose Rate Brachytherapy, Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Cancer
Interventions: Stereotactic radiation Arm 1, Stereotactic radiation Arm 2, Stereotactic radiation Arm 3, Stereotactic radiation Arm 4; Radiation
Lead sponsor: Dr Thomas DiPetrillo; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Pawtucket, Rhode Island • Providence, Rhode Island

Conditions: Brain Cancer
Interventions: Arsenic Trioxide, Stereotactic radiosurgery; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Cancer, Metastatic Pancreatic Cancer
Interventions: M7824, M9241, SBRT; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Dose Fractionation; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 2
States / cities: Baltimore, Maryland • Dallas, Texas

Conditions: Squamous Cell Carcinoma
Interventions: Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for infusion, Avelumab, bevacizumab, Capecitabine, Cetuximab, Cisplatin, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, Necitumumab, SBRT, N-803; Drug · Biological · Procedure
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: El Segundo, California

Conditions: Liver Cancer
Interventions: stereotactic body radiation therapy; Radiation
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Early Stage Breast Cancer
Interventions: Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: Stereotactic Body Radiation Therapy SBRT; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 50 Years to 100 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Metastatic Melanoma
Interventions: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Malignant Glioma
Interventions: Hypofractionated Stereotactic Irradiation (HFSRT), Pembrolizumab, Bevacizumab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Malignant Solid Neoplasm
Interventions: Advanced Magnetic Resonance Imaging, Conventional Magnetic Resonance Imaging, Gadolinium-Chelate, Iopamidol; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Malignant Glioma
Interventions: Hypofractionated Stereotactic Irradiation, Nivolumab, Bevacizumab, Ipilimumab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Tampa, Florida • Columbus, Ohio

Conditions: Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Abiraterone Acetate, Apalutamide, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Drug · Other · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Adenocarcinoma of the Prostate
Interventions: Radiation Therapy, Androgen Deprivation Therapy (ADT); Radiation · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland

Conditions: Primary Renal Cancer
Interventions: MRI-guided linear accelerator, Magnetic resonance imaging (MRI)-guided radiation therapy (MRgRT); Device · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Lung Neoplasm, Metastatic Malignant Neoplasm in the Lung, Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer
Interventions: CAPP-Seq, Isovue-200, Computed Tomography Perfusion Imaging; Device · Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Atezolizumab 1200 MG in 20 ML Injection, Stereotactic Body Radiation Therapy, Varlilumab 3 mg/kg; Drug · Radiation
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Breast Cancer
Interventions: 5 Fraction Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama

Conditions: Glioblastoma Multiforme
Interventions: Pembrolizumab, Stereotactic Radiation Therapy, Surgical Resection; Drug · Radiation · Procedure
Lead sponsor: Chirag G. Patil; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glioblastoma
Interventions: Intensity Modulated Radiation Therapy, Temozolomide, Functional Assessment of Cancer Therapy-Brain (FACT-Br), Stereotactic Radiosurgery Boost, Simultaneous Integrated Boost, 3D MRSI; Radiation · Drug · Behavioral + 1 more
Lead sponsor: University of Miami; Other
Eligibility: 19 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer

Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer

Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma

High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma

Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer

Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer

Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer

Study of Stereotactic Radiotherapy for Breast Cancer

SBRT as a Vaccination for Metastatic Melanoma

Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas

Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis

Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Radiation and Androgen Ablation for Prostate Cancer

Stereotactic MR-Adaptive Radiation Therapy for Early-stage Renal Cancer

CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)

Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma